11.11.2025 23:15:10 CET | Thor Medical ASA | Mandatory notification of trade primary insiders

Reference is made to the stock exchange announcement made by Thor Medical ASA, the "Company") on 21 April 2024 regarding grant of restricted share units ("RSU") to the members of the board.

The Company's board of directors has today resolved to issue 1,090,974 new shares in the Company pursuant to the RSU-program. Current board members, John Andersen and Mimi Kristine Berdal, have each been issued 344,518 new shares. John Andersen has agreed to transfer all 344,518 shares to Scatec Innovation AS, where John Andersen is the CEO, a close associate of a primary insider of the Company.

Notifications of the transaction in accordance with the Market Abuse Regulation Article 19 are attached with this announcement.

‍

Contacts

Brede Ellingsæter

CFOO

Thor Medical ASA

Tel: +47 472 38 440

brede.ellingseter@thormedical.com

‍

About Thor Medical ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’. 

‍

Attachments

Download announcement as PDF.pdf

20251111 - TRMED - MAR forms RSU share issue 2025.pdf

20251111 - TRMED - MAR forms Scatec Innovations_John Andersen RSU share transfer.pdf‍